Aravax's PVX108 Receives FDA Fast Track Designation for Peanut Allergy

FDA has granted fast track designation to Aravax's PVX108, a peptide-based immunotherapy for peanut allergy. Fast track status is intended for therapies treating serious or life-threatening conditions that demonstrate the potential to address unmet medical needs, and can make a drug eligible for more frequent FDA meetings and written communication, rolling review of a future marketing application, and eligibility for priority review and accelerated approval if certain criteria are met.¹

"There remains a critical need for effective new treatments for food allergy and we believe PVX108 has the potential to offer a safer, more convenient and disease modifying treatment for the millions affected by peanut allergy worldwide," said Pascal Hickey, PhD, CEO of Aravax, in a company press release.¹ "Receiving FDA fast track designation is a significant step for PVX108's future development, as being able to communicate more frequently with [FDA] often leads to early drug approval and access by patients."

What is the current treatment landscape for peanut allergy?

Peanut allergy affects an estimated 1% to 2% of children in the United States and other Western countries and is a leading cause of severe, potentially fatal food-induced anaphylaxis.² Current management relies primarily on strict dietary avoidance and rescue epinephrine. Palforzia, an oral peanut protein powder, remains the only FDA-approved immunotherapy for peanut allergy, approved in January 2020 for children aged 4 to 17 based on the phase 3 PALISADE trial.²

How does PVX108 work, and what data exist so far?

PVX108 consists of 7 proprietary synthetic peptides, each representing immunodominant T-cell epitopes from major peanut allergens, designed to retrain allergen-specific T cells while avoiding the acute allergic reactions associated with whole-allergen immunotherapy approaches.^1,3 In an earlier phase 1 study, PVX108 produced immune changes in response to peanut protein that continued to develop after dosing had concluded, marking it the first peptide-based immunotherapy for food allergy to be administered to patients.³

The ongoing phase 2 trial (NCT05621317), conducted under an FDA investigational new drug application, is a double-blind, placebo-controlled study evaluating 2 dose levels of PVX108 against placebo, administered monthly over 44 weeks, in children and adolescents aged 4 to 17 with peanut allergy; the primary endpoint is the change in maximum tolerated dose of peanut protein on food challenge relative to baseline.⁴ The trial enrolled 95 patients across 8 sites in the US and 6 in Australia, and the company has said headline results are anticipated later in 2026.^1,4

What are the limitations?

Fast track designation does not necessarily guarantee that PVX108 will be approved, and the benefits associated with the designation depend on FDA agreement at each stage of development. Phase 2 efficacy and safety data have not yet been reported.

References

1. Aravax. Aravax awarded FDA fast track designation for PVX108, a next-generation immunotherapy for the treatment of peanut allergy. Press release. Published August 3, 2026. Accessed August 3, 2026. https://www.aravax.com.au/aravax-awarded-fda-fast-track-designation-for-pvx108-a-next-generation-immunotherapy-for-the-treatment-of-peanut-allergy/
2. The PALISADE Group of Clinical Investigators. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991-2001. doi:10.1056/NEJMoa1812856
3. Voskamp AL, Khosa S, Phan T, et al. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy. Allergy. 2023;79(2):485–498. doi:10.1111/all.15966
4. Aravax. Aravax completes recruitment into phase 2 study of PVX108, a novel immunotherapy for the treatment of peanut allergy. Press release. Published October 28, 2024. Accessed August 3, 2026. https://www.aravax.com.au/aravax-completes-recruitment-into-phase-2-study-of-pvx108-a-novel-immunotherapy-for-the-treatment-of-peanut-allergy/